bevacizumab/Avastin
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
... or bevacizumab (Avastin®) on the corneal endothelium of human organ-cultured donor corneas were ...and bevacizumab (Avastin®) incubation could be ...
8
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
... Metastatic clear cell renal cell carcinomas (mRCC) over-express the vascular endothelial growth factor (VEGF). Hence, the anti-VEGF antibody bevacizumab/Avastin (BVZ) combined with interferon alpha (IFN) ...
15
Pharmacokinetics of intravitreal bevacizumab (Avastin<sup>®</sup>) in rabbits
... Bevacizumab concentrations were measured using enzyme- linked immunosorbent assay (ELISA). Two ELISA meth- ods were used, one of low sensitivity (LS ELISA, linear range: 5 ng/mL to 0.1 µ g/mL, Figure 1A) and one ...
8
Is monthly retreatment with intravitreal bevacizumab (Avastin<sup>®</sup>) necessary in neovascular age-related macular degeneration?
... While the results of this study are encouraging, several shortcomings are worth mentioning. These include the retrospective design with varying baseline characteristics of included eyes, short-term follow up, small ...
8
The effect of intravitreal bevacizumab (Avastin<sup>®</sup>) on ocular pulse amplitude in neovascular age-related macular degeneration
... of bevacizumab or any other anti- VEGF treatment on OPA in AMD or in any other ocular ...off-label bevacizumab, at a ...of bevacizumab that reached the choriocapillaris within the first week post- ...
8
COMPARISON OF INTRAVITREAL BEVACIZUMAB (AVASTIN) WITH TRIAMCINOLONE FOR TREATMENT OF DIFFUSED DIABETIC MACULAR EDEMA: A PROSPECTIVE RANDOMIZED STUDYAli Kasiri, Fereydoun Farrahi, Mostafa Feghhi, Behnam Sadeghi, Hesam Hedayati, Seyed Ahmad Rasoulinejad DOWNLOAD/VIEW
... diseases. Bevacizumab is a pan-VEGF-blocking agent and may impair normal physiologic VEGF- mediated functions, which might be considered as a disadvantage of this ...
9
A randomised, double masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age related macular degeneration: clinical trial design
... Another novel design feature is the use of pro re nata treat- ment with bevacizumab (based on investigator deter- mined retreatment with standardised retreatment criteria) after three initial treatments. This ...
12
The Results of Intravitreal Bevacizumab Injections and Laser Photocoagulation for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
... agents, Bevacizumab (Avastin) (Genentech, USA), Ranibizumab (Lucentis), have been in increasing use in macular edema following a retinal vein occlusion ...[7,8]. Bevacizumab, despite not being ...
5
Effect of Photodynamic Therapy and Anti-VEGF Therapy in the Treatment of Corneal Neovascularization : (FTIR) Study Mohamed I. El Gohary* 1, Salwa A. Abdelkawi2 , Aziza A. Hassan 3and Ayman S. El Shinawy4
... The aim of the present study was to compare the effect of photodynamic therapy (PDT) by using argon laser and bevacizumab (Avastin) on corneal neovascularization (CNV) in rabbits. Thirty-Nine New Zealand ...
8
STERILITY OF BEVACIZUMAB INJECTION VIALS ON MULTIPLE DOSAGE USE FOR INTRAVITREAL INJECTIONS
... injection Bevacizumab (Avastin) vials used for multiple dosage in consecutive cases and to report incidence of post injection endophthalmitis Methods: this is a prospective study of over a period of 20 ...
7
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
... Abstract: Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of ...
11
Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach
... Two phase III randomized studies (GOG- 218 [36] and ICON-7 [37]) have recently demonstrated the efficacy of bevacizumab (recombinant monoclonal antibody that binds with a high affinity to VEGF-A) in adjunct to ...
12
From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials an interview with Napoleone Ferrara
... of bevacizumab and other VEGF pathway inhibitors, such as small molecule tyrosine kinase inhibitors, for various ...with Avastin survived longer but they eventually succumbed to the ...of Avastin ...
7
Vol 26, No 4 (2013)
... Foi realizada uma pesquisa electrónica nas bases de dados Medline (Pubmed) e Cochrane Library (CENTRAL) até Fevereiro de 2013. A estratégia de pesquisa utilizada para a Medline incluiu a combinação dos termos relacio- ...
11
A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
... variability may account for the lack of statistical significance. There were two patients in the ranibizumab only group that had remarkably large visual gains (55 and 63 letters). These patients skewed the mean visual ...
7
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
... retinal pigment epithelium tear, retinal detachment, and increased IOP to be ,1% in the studied eyes. The authors noted that increased IOP was usually transient and in all but one case, controlled with medications. ...
10
Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases
... of bevacizumab/irinotecan-based ...of bevacizumab led to a pathologic response rate similar to that in the chemotherapy-alone subgroup but led to a higher pathologic response rate than that in the ...
11
Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity
... During the study period, 3233 preterm infants born <29 weeks’ GA were admitted to 1 of the participating NICUs of the CNN, of which 1154 were diagnosed with ROP (Fig 1). Among them, 174 were treated for ROP: 37 had ...
10
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
... for bevacizumab- and sorafenib-induced HT and HFSR is currently unknown although they most likely originate from the activity of these drugs altering signaling through several targets ...
8
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
... for bevacizumab/carboplatin/ paclitaxel was 10 months, which was slightly less than the median PFS reported in ECOG-2100 of ...The bevacizumab arm reported more toxicity as regards to hypertension and ...
6